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a  b  s  t  r  a  c  t
Over  the  past  few  decades  the extent  to which  cytotoxic  T  lymphocytes  (CTLs)  control  human  immuno-
deﬁciency  virus  (HIV)  replication  has  been  studied  extensively,  yet  their  role  and  mode  of action  remain
controversial.  In  some  studies,  CTLs  were  found  to kill  a large  fraction  of  the  productively  infected  cells
relative  to the  viral  cytopathicity,  whereas  in  others  CTLs  were  suggested  to kill  only  a  small  fraction  of
infected  cells.  In this  review,  we  compile  published  estimates  of CTL-mediated  death  rates,  and  examine
whether  these  studies  permit  determining  the rate  at which  CTLs  kill  HIV-1  infected  cells.  We  high-
light  potential  misinterpretations  of the CTL-killing  rates  from  the  escape  rates  of  mutants,  and  from
perturbations  of  the  steady  state  viral  load  during  chronic  infection.  Our  major  conclusion  is that  CTL-
mediated  killing  rates  remain  unknown.  But  contrary  to  current  consensus,  we  argue  that  killing  rates
higher  than  one  per  day  are  perfectly  consistent  with  the  experimental  data,  which  would  imply  that
the  majority  of the  productively  infected  cells  could  still  die  from  CTL-mediated  killing  rather  than  from
viral  cytopathicity.
© 2015  The  Authors.  Published  by Elsevier  B.V.  on behalf  of  European  Federation  of Immunological
Societies. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).. Introduction
CD8+ cytotoxic T lymphocytes (CTLs) are an indispensable arm
f the adaptive immune system for protection against tumors,
nd against viral and bacterial infections. CTLs protect by killing
nfected cells and by various non-lytic mechanisms, including
he secretion of interferon- , macrophage inﬂammatory proteins
MIP)-1  ˛ and MIP-1ˇ [1,2]. The relative contribution of these two
echanisms in controlling infections is poorly understood, and an
mportant parameter determining the extent of CTL protection is
he rate at which they kill infected cells. Although CD4+ T cells
hat have become productively infected with the human immu-
odeﬁciency virus type 1 (HIV-1) are known to die rapidly [3,4],
ecent studies into the role of CTLs in controlling HIV-1 infection
ave suggested that their mode of action is largely non-lytic [5–9].
his would imply that the majority of the productively infected
ells are not killed, but die rapidly from infection (viral cytopathic-
ty). Here we review these studies to see if they indeed support the
inor contribution of the lytic effects of CTLs, and whether they are
∗ Corresponding author.
E-mail address: s.gadhamsetty@uu.nl (S. Gadhamsetty).
ttp://dx.doi.org/10.1016/j.imlet.2015.07.009
165-2478/© 2015 The Authors. Published by Elsevier B.V. on behalf of European Federat
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).truly incompatible with rapid CTL killing rates. There are multiple
ways to report CTL-mediated killing rates (see [10–12] for excel-
lent overviews and how to interconvert these rates). In this review,
we report published estimates of killing rates as the death rate of
productively infected cells induced by all CTLs together.
Several kinetic parameters of HIV-1 and SIV infections are simi-
lar. During acute infection in their respective hosts, the two viruses
initially replicate at comparable rates of 1.5–2.0/day [13–16], and
during anti-retroviral therapy (ART) they exhibit similar viral load
decay rates of 1–2/day [6,7,17,18]. One notable difference between
HIV-1 and SIV is that HIV-1 immune escape rates were consis-
tently lower than SIV escape rates [19]. Here, we primarily focus
on CTL-mediated killing rates during HIV-1-infection and discuss
a few published SIV estimates from studies that can only be per-
formed in monkeys. As a side note, there is an ongoing debate on
whether the CD4+ T cell depletion and loss of HIV-speciﬁc immu-
nity in longterm HIV patients is primarily due to CTL responses or
to HIV-induced inﬂammation [20,21]. Our conclusions are indepen-
dent of the mechanism(s) underlying CD4+ T cell depletion, because
the depletion of CD4+ T cells during chronic infection occurs slowly
(typically on a time scale of years), whereas the mathematical
models discussed in this review only consider the faster dynamics
occurring on a time scale of days.
ion of Immunological Societies. This is an open access article under the CC
2 unolo
2
m
o
t
a
c
t
e
m
t
c
f
H
r
r
2
f
a
s
s
i
C
S
a
t
m
m
C
s
p
q
r
e
f
b
i
b
n
h
u
g
r
v
t
w
i
t
q
b
f
r
e
F
c
t
s
i
i
e
f S. Gadhamsetty et al. / Imm
. Estimating killing rates from escape rates
HIV and SIV mutate when they infect new target cells. If these
utations occur within CTL epitopes, they can reduce the ability
f CTLs to recognize and control infected cells, thereby allowing
he virus to escape CTL surveillance. Such escape mutants have
 selective advantage over wild type viruses, and hence can out-
ompete them. The rate at which escape mutant replaces the wild
ype—deﬁned as the escape rate—provides an indication of the
fﬁciency of the CTL response that was evaded. However, escape
utations are often accompanied by ﬁtness costs of the muta-
ions, which slow down the escape rate [11,5]. The ﬁtness costs
an be estimated in vitro by competition assays [22–24] and in vivo
rom the rates at which escape mutants revert back to wild type in
LA-mismatched patients [5,25,26]. By accounting for ﬁtness costs,
esearchers have tried to estimate the in vivo CTL-mediated killing
ate from the escape rates of mutants (reviewed in [11]).
.1. Early escape rates
Asquith et al. [5] examined longitudinal measurements of the
requencies of immune escape mutants and found very slow escape
nd reversion rates in 12 HIV-1-infected individuals at different
tages of infection. Combining the estimated escape and rever-
ion rates, and considering a model where CTLs control by killing
nfected cells, they estimated a median killing rate by the escaped
TL response of 0.04/day during the acute phase of the infection.
ince the total death rate of productively infected CD4+ T cells is
bout ı = 1/day [17] (see below), they concluded that a CTL response
argeting a single epitope is responsible for the death of only a
inor fraction of virus-producing cells, i.e., at most 4%. In patients
ounting CTL responses to, say, ﬁve epitopes, the contribution of
TL killing to the death of productively infected CD4+ T cells would
till be just 20%, suggesting that most infected cells die by viral cyto-
athic effects. Although later studies using the same approach fre-
uently ﬁnd at least 10-fold faster escapes [27–29] and more rapid
eversions [26], other recent studies conﬁrm that both immune
scapes and reversions can be slow [30]. One possible explanation
or these slow immune escape rates is that CTLs largely control
y non-lytic mechanisms [9]. Immune escapes from non-lytic CTLs
mpose lower selection pressures than escapes from lytic responses
ecause cells infected with escaped virus remain susceptible to
on-speciﬁc factors secreted by the CTL in their neighborhood [9].
At least two other explanations for slow immune escape rates
ave been suggested, both implying that the published escape rates
nderestimate the actual CTL killing rates. First, there are some
eneral issues associated with estimating killing rates from escape
ates, i.e., by sequencing the HIV-1 quasi species in a patient at
arious time points and ﬁtting simple population genetic models
o the time course describing the fraction of mutated sequences
ithin each epitope [31]. One major problem with such models
s that the escapes are treated independently, whereas in reality
he immune escapes appear more or less sequentially, i.e., subse-
uent escapes can only evolve after previous immune escapes have
ecome established. This competition is known as “clonal inter-
erence” in population genetics [32,33], and several authors have
ecently shown that clonal interference can markedly decrease the
scape rate inferred independently for each epitope [31,34–37].
or example, Kessinger et al. [35] developed a novel mathemati-
al model combining the escape data from all epitopes, and showed
hat their estimation procedure markedly increased the most likely
et of escape rates. Another major problem with this kind of data
s that the time courses are underpowered due to sampling that
s fairly infrequent [38] and that is not deep enough to detect the
xact arrival time of the escape mutants. By testing clonal inter-
erence models on simulated data, it was indeed found that thegy Letters 168 (2015) 1–6
estimated escape rates are very sensitive to the sampling frequency
and to the sequencing depth [35,37], casting additional doubt on
the estimated escape rates [31,35]. Next generation sequencing
(NGS) methods have been used to sequence much deeper [39],
but due to their prohibitive costs, the sampling frequency remains
limited. An interesting approach is to reconstruct whole genome
haplotypes from the NGS data [40], which allows one to observe
the clonal interference directly and to estimate the escape rate of
all the major haplotypes.
A second line of explanations for slow immune escape that does
not involve non-lytic mechanisms is that large ﬁtness costs can
explain at least some of the slow escapes observed. Several immune
escapes confer severe ﬁtness defects, which can be observed in vivo
by poor replication of the virus in subsequent HLA-mismatched
patients [26] or in vitro by viral competition assays [24,22,23]. Addi-
tionally, the reversion rates estimated in vivo also suffer from clonal
interference, and could hence be markedly underestimated. Finally,
several immune escape mutations ultimately become repaired by
compensatory mutations increasing the replicative ﬁtness of the
virus. Following transmission to HLA-mismatched patients such a
repaired immune escape may  have a high ﬁtness, and hence reverts
very slowly.
2.2. Late escape rates
In the study by Asquith et al. [5] the immune escape rates
tended to be even slower in chronically infected patients, i.e., about
0.008/day than in acute stage. They were also found to decrease
over time in a study following three HIV-1-infected individuals
over one year [28]. Moreover, a recent study following about
120 HIV-1-infected individuals starting at a median of 11 weeks
post seroconversion found very few escapes over the subsequent
2–3 years of chronic infection [30]. The apparent decrease in the
immune escape rate has been attributed to a lower killing efﬁciency
during chronic infection due to exhaustion of CTLs [5,12,31], and
due to the decrease in CTL numbers after the acute phase [11].
However, other explanations for the escape rate decrease over
time are possible. First, a trivial explanation could again be the
small number of time points in these studies, because the samp-
ling frequency typically decreases over time [37]. Second, similar
observations have been made in mathematical models in which the
data is “sampled” very frequently [38]. Van Deutekom et al. [41] and
Ganusov et al. [28] demonstrated that escape rates are expected to
decrease during chronic infection due to an increase in the number
of CTL responses. This is because multiple CTL responses can collec-
tively induce rapid death, while the contribution of each individual
CTL response remains small. As a result, the selective advantage for
the virus to escape just one CTL response decreases [41], leading to
slow escape. Consistent with this, a recent study showed that broad
Gag responses are associated with few escapes and low viral load
in HIV-1-infected individuals [42]. Thus, slow escape rates during
chronic infections are to be expected for broad immune responses,
and are not indicative of non-lytic or poor control by CTLs.
Summarizing, the current data on the immune escape and
reversion rates in HIV-1 infection have been described with over-
simpliﬁed mathematical models, and are not rich enough for
reliably estimating the contribution of CTLs during the acute and
chronic phases of HIV-1 infection, let alone the relative contribution
of lytic and non-lytic mechanisms. Fortunately, with the current
rise of NGS approaches [39,40], and the novel models taking clonal
interference into account [31,34–37], this is expected to improve
once we can afford to sample the viral quasi species very frequently.
This is important because immune escape and reversions provide
natural in vivo experiments providing information on the role of
CTLs in HIV-1 infection.
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. Estimating killing rates from ART data
During chronic HIV/SIV infection, the plasma viral load remains
onstant over many years due to the balance between viral
eplication and clearance mechanisms, i.e., a steady state. In sev-
ral studies the steady state was perturbed, and the ensuing viral
ynamics were analyzed to estimate the kinetic parameters of viral
eplication and CTL-mediated killing rates. The approaches used
o perturb steady state can be classiﬁed into three broad cate-
ories: treatment with anti-retroviral therapy (ART), depletion of
D8+ cells, or adoptive transfer of CD8+ T cells. In the remainder of
his review, we focus on estimates of killing rates during chronic
IV/SIV infection obtained using these three methods.
Ho et al. [3] and Wei  et al. [4] examined the dynamics of HIV-
 following ART with one or two protease inhibitors, and found
hat the plasma viral load declines very rapidly after treatment.
n later studies, the viral load was found to decline in multiple
hases [43,44], and using an even more potent combination of
rugs [17], it was found that the initial downslope of the viral load
s about ı = 1/day. These downslopes were estimated by ﬁtting a
asic model (Fig. 1A, [46]) to the viral load, in which this initial
ownslope, ı, reﬂects the death rate of productively infected CD4+
 cells [3,4,43,44,17].
A meta-analysis of various clinical data sets showed that ı hardly
epends on the CD4+ T cell count or on the pre-treatment viral
oad [18]. This was surprising because the death rate of produc-
ively infected CD4+ T cells represents both “normal death” and CTL
illing, i.e., ı = dP + K, where dP is the normal death rate (including
iral cytopathic effects), and K is the rate at which infected cells are
illed. Since ı was so invariant in the meta-analysis, and patients
ith different viral loads probably have different CTL responses, it
as proposed that CTLs hardly affect the death rate of productively
nfected CD4+ T cells [18]. This is reminiscent of the minor contribu-
ion of killing estimated from the escape rates [5] and hence again
uggests that CTLs largely control by non-lytic mechanisms.
Recently, Klatt et al. [6] and Wong et al. [7] independently stud-
ed the contribution of CTL-mediated killing, K, during SIV-infection
o the death rate of productively infected cells, ı. The viral dynam-
cs were studied following ART in both CD8+ cell-depleted and
ontrol rhesus macaques infected chronically with SIV. Note that
argeting the CD8 molecule for CTL depletion also depletes other
D8-expressing cells (such as NK cells) [6]. Nevertheless, the rate
t which the plasma viral load declined was similar between CD8-
epleted and control macaques. By ﬁtting the basic model (see
ig. 1A) to the viral load, the authors estimated similar death rates,
, of virus-producing cells in CD8-depleted (where ı = dP) and con-
rol hosts (where ı = dP + K). Because this implies that K is very small,
his again suggests a negligible role of CTLs in the death of virus-
roducing cells.
.1. Interpreting ART and CD8-depletion data with two-stage
athematical models
The above studies estimated lifespans of the productively
nfected cells using the basic model of virus dynamics (Fig. 1A),
hich ignores several aspects of viral replication that are rele-
ant to HIV-1 infection. For instance, it does not account for the
clipse phase, i.e., the time period between viral entry and produc-
ion of viruses [45]. In other words, the basic model assumes that
he infected cells start producing virus particles immediately after
nfection.
Klenerman et al. [47] developed an HIV/SIV-speciﬁc mathe-
atical model that includes two infected cell stages and a viral
roduction stage for the infected cells (i.e., three-stage viral repli-
ation; similar to the two-stage model shown in Fig. 1B). They
ssumed that antigen expression and ensuing recognition by CTLsgy Letters 168 (2015) 1–6 3
only occurred in the viral production stage (late-stage killing
model). Furthermore, they argued that the rate,  , at which HIV-
infected cells transit to antigen-expressing stage is the slowest
timescale of HIV replication. In that case, the observed downslope
of the viral load during ART, ı, reﬂects this slow transition rate.
Because the average duration of the eclipse phase, 1/ , is about
one day [45], this is in excellent agreement with a decay rate of
ı = 1/day, and with the independence of the viral load and the CD4+
T cell count [17,18].
Further, when Wick et al. [49] performed stochastic simulations
similar to the late-stage killing model with a rapid CTL-mediated
killing rate of K ≈ 7/day, they found approximately equal viral
decay rates between CD8-depleted and control hosts when  was
the rate limiting step. Although the Wick et al. [49] simulation
model differs from the late-stage killing model in several details,
analysis of a similar deterministic model (Fig. 1B) conﬁrms its
consistency with the CD8-depletion experiments (i.e., viral decay
rate reﬂects  + dI; Fig. 2A). Therefore, in both the two- and
three-stage variants of the late-stage killing model, CTL-mediated
killing can be rapid, if it acts only in late stages of infection [47,49]
and thus separates the timescales of viral replication and CTL
lysis. However, Klatt et al. [6] argue that the time scale of infected
cells in the eclipse phase is not necessarily slow, because some
HIV epitopes are expressed on infected cells as early as an hour
after infection [50]. Thus, infected cells could be susceptible to
CTL-mediated killing immediately after infection.
It is unclear whether the timescale of the eclipse phase is indeed
the slowest process in the short life of productively infected cells.
Therefore, Althaus et al. [48] used the mathematical model of
Fig. 1B to show that early antigen expression followed by rapid CTL-
mediated killing of infected cells at an early stage within the eclipse
phase (early-stage killing model) is also consistent with the simi-
lar decay rates of viral loads observed in CD8-depleted and control
hosts (Fig. 2B). Because CTLs in this model only kill infected cells
in the eclipse phase, the viral decay rates are independent of CTL
activity. These decay rates now represent the death rate of virus-
producing cells, which can be large due to viral cytopathicity alone
(i.e., ı = dP; Fig. 1).
In conclusion, the viral load dynamics is determined by the
timescale of the slowest process, and CTL lysis need not be slow.
The two-stage model is a simple extension of the basic model,
and underlines how the rate limiting step alters the interpretation
of the initial viral decay. More sophisticated models either with
multiple cellular compartments [52,43], or with n stages from
infection to viral production [53,54] have been proposed for a
complete description of all three phases of viral decay. Neverthe-
less, the two-stage model with CTL-mediated killing of infected
cells either in the early or late stage can qualitatively explain the
results from ART studies (phase I) with or without CD8-depletion.
Importantly, this implies that the rate of CTL-mediated killing can
be larger than 1/day.
3.2. Which model quantitatively describes the ART and
CD8-depletion data best?
Recently, Elemans et al. [8] studied whether or not the above
models (i.e., the basic, early-stage killing, and late-stage killing;
Fig. 1) can provide a good quantitative description of the CD8 deple-
tion/ART data of Klatt et al. [6]. Fitting these models to the data, they
found that all three models poorly described the experimental data
[8]. This is puzzling as both Klenerman et al. [47] and Althaus et al.
[48] demonstrated that their respective models are qualitatively
consistent with the experiments over a wide range of parameters. A
potential explanation for these conﬂicting ﬁndings is that Elemans
et al. [8] required the target cell levels in the model to describe
the observed CD4+ T cell counts, and considered the speciﬁc CTL
4 S. Gadhamsetty et al. / Immunology Letters 168 (2015) 1–6
Fig. 1. Summary of various models used to describe HIV dynamics. The scheme summarizes the three models discussed: (A) basic and (B) two-stage infection models in
which  CTL-mediated killing acts either during eclipse phase or during virus-production phase. HIV viral particles, V, infect healthy CD4+ T cells, T, at a rate ˇ. Following
infection, infected cells, I, transit the eclipse phase at a rate  to become virus-producing cells, P, which produce new virus particles. Healthy CD4+ T cells are produced at a
constant  rate, , and die at a rate dT , and free virus particles are cleared at a rate c. Infected cells in the eclipse phase, I, and productively infected cells, P, die normally at a
rate  dI and dP , respectively. Additionally, they can be killed by CTL at a rate K, which, depending on the model increases their total death rates to ıI and ıP , respectively. The
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iredicted viral decay rates, ı, are summarized in the accompanying table, where m
rom  the two-stage models by making the eclipse phase very short (i.e., by letting 
esponse to be proportional to the observed CD8+ T cell counts.
ontrary to these assumptions, the frequency of HIV-speciﬁc CTLs
ithin the pool of CD8+ T cells could change over time following
D8 depletion, and the total number of CD4+ T cells is probably a
oor indicator for the number of susceptible target cells. Thus, it
emains possible that the two-stage models shown in Fig. 1B can
uantitatively account for the viral load data.
. Estimating killing rates from the increase of the viral
oad upon CD8-depletion
In all studies where CD8+ cells are depleted in chronically SIV-
nfected macaques it was consistently found that this results in a
apid transient increase of the viral load [6,7,55], suggesting that
D8-depletion results in an imbalance between viral production
nd clearance. Indeed, there was a negative correlation between the
esidual CD8+ T cells surviving the depletion and the fold-increase
ig. 2. Predictions of the decay of virus-producing cells following ART with or without CD
B).  Solid blue lines depict the dynamics of productively infected cells, P, upon ART star
ollowed by ART starting at day 3. Dashed black lines depict the expected decline of viru
he  actual CTL killing rate in both models was about K = 4.8/day. The dynamics were co
′ =  − dTT − ˇTV, I′ = ˇTV − ıII − I, P′ = I − ıPP and V = P, with  = 106 cells/day, dT = dI = 0
unctions and parameters as in [41], i.e., E′ = pEA/(h + A + E) − dEE and K = kE,  where the am
arly-stage killing model, and p = 1.1/day, dE = 0.1/day and k = 4 ×10−5. In the early-stage 
hat  decay rates are consistent with the experimental observations, i.e., ı = dP , whereas dP
emains the slowest time scale even after CD8-depletion). Infection rates, ˇ, for both mode
 = 9.1 × 10−7 for the late-stage killing model, and 6.5 × 10−7 for the early-stage killing m
s  referred to the web version of the article.)y) represents the minimum of x and y. Note that the basic model can be obtaining
.
in the viral load [7]. Because the killing rate at steady state was  fast,
both the early- and late-stage killing models readily account for
such a rapid increase of the viral load increase upon CD8 depletion
(Fig. 2), and both are consistent with the experimental observa-
tions. Since the killing rate in the basic model should not be faster
than ı = 1/day, the basic model can only account for these data if
the major effect of CTLs is non-lytic [56].
A few studies directly estimated the CTL-mediated death rate
by equating it to the rate at which the viral load increases upon
CD8-depletion [6,7], and arrived at a killing rate between 0.25 and
0.8/day [7,8]. In the basic model of Fig. 1A one indeed expects the
upslope of the viral load to reﬂect the killing rate K, but in the multi-
stage models of Fig. 1B this is more complicated. Generally, the rate
at which the viral load increases upon CD8-depletion reﬂects the
effective replication rate of the virus in the chronic steady state just
before the CD8+ T cells were depleted. Compared to acute infec-
tion, the number of CD4+ T cells is decreased during chronic stage.
8-depletion in the late-stage killing model (A) and in the early-stage killing model
ting at day 0. Solid red lines indicate their dynamics upon CD8-depletion at day 0
s-producing cells at a rate 1/day. During chronic infection, before CD8-depletion,
mputed with the differential equations corresponding to the scheme of Fig. 1B:
.1/day, and  = 1/day. The CTL dynamics and killing of infected cells obey the same
ount of antigen, A, is deﬁned by P in the late-stage killing model, and by I in the
killing model, a death rate of dP = 1/day is used for productively infected cells such
= 2/day is used in the late-stage killing model (to guarantee that the eclipse phase
ls are chosen following [51], such that the initial viral growth is 1.5/day (speciﬁcally
odel). (For interpretation of the references to color in this ﬁgure legend, the reader
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herefore, the availability of suitable target cells should also be low
t the onset of the CD8-depletion, and the rate at which the viral
oad increases is expected to be lower than during acute infection,
.e., approximately 1.5/day [13–15,57]. Indeed, the observed viral
oad increases of 0.25–0.8/day [7,8] are consistent with this reason-
ng. Similar rates of viral load increase, about 0.3–1.2/day, occur in
ther CD8-depletion studies [55,56,58,59]. In the model simula-
ions of CD8-depletion (Fig. 2) the productively infected cells, and
ence the viral load, increased at a realistic rate of about 1.3/day,
hereas the CTL-mediated killing rate at steady state was almost
/day. Therefore, the rate at which the viral load increases upon
D8-depletion need not always reﬂect the killing rate, and rapid
illing rates can be consistent with the moderate viral load increase
ates observed in the data.
. Killing rates from adoptive transfer studies
More than a decade ago, Brodie et al. [60] transferred ex-vivo
ctivated HIV-speciﬁc CTLs into chronically HIV-1-infected indi-
iduals, and followed the resulting dynamics of productively
nfected cells (deﬁned by the expression of HIV-mRNA) and CTLs
n the blood. To the best of our knowledge, this is the only study
nvolving adoptive transfer of CTLs into HIV-1-infected humans,
nd provides an opportunity to directly estimate the killing rates.
itting a mathematical model to these measurements, Wick et al.
61] estimated the killing rate due to the transferred CTLs as
anging from 1.6/day to 9.8/day [61,12]. This range thus represents
he highest killing rate estimate so far.
However, the model by Wick et al. [61] described the data rather
oorly, particularly around 4 days post CTL transfer, at which time
he CTLs in the blood reached nadir. This could be because the
imulations considered only CTLs and infected cells in the blood,
gnoring their interactions in lymphoid tissues. Indeed, at day 4
rodie et al. [60] found 10-fold more CTLs in lymph nodes (LNs)
han in the blood. Moreover, LN-residing CTLs preferentially co-
ocalized with HIV-infected cells, suggesting that CTLs in the LN
ontinue to kill infected cells at this time point. Because the fre-
uency of CTLs in the LNs was measured at only a single time point,
t remains unknown whether they preferentially accumulated in
he LN, and what fraction of killing occurs in the LN. Therefore, the
stimated death rates are likely inaccurate.
. Conclusions
Over the past decades, researchers have used various experi-
ental and modeling approaches to determine the importance of
TLs in mediating lytic control of HIV-1 infection. In this review, we
ave examined several estimates for CTL-mediated death rates of
IV-1 infected cells. We  conclude that there is currently not a sin-
le robust estimate, and have highlighted some of the difﬁculties
ssociated with inferring killing rates from escape rates. Unfortu-
ately, models where productively infected cells are killed largely
t an early stage [48], at a late stage [47], or where CTL action
ccurs largely through non-lytic effects [8] can all explain the data,
nd it thus remains unknown which of them is correct. This calls
or novel experiments that can distinguish between these mecha-
isms. In conclusion, published estimates of CTL-mediated killing
ates remain uncertain, and we have only added to this uncertainty
y arguing that rapid killing rates are also consistent with the data.
hus, CTL killing could after all be the major cause of death of
roductively infected CD4+ T cells.onﬂict of interest
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